Sorry, you need to enable JavaScript to visit this website.

    Pfizer to Share New Data and Portfolio Update on Infectious Disease Portfolio at ICAAC Meeting; Invites Public to View and Listen to Webcast of September 18 Analyst Meeting

    (BUSINESS WIRE)--Pfizer Inc said today that the company plans to present key data on in-line medicines and pipeline research at the Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, Illinois. In addition, Pfizer plans to host an investor meeting on September 18th to review key updates on infectious disease medicines and pipeline research. The meeting will be webcast live from Chicago.

    Pfizer will present more than 50 abstracts on a range of new findings across bacterial, fungal and viral disease research at the ICAAC meeting.

    Pfizer has a rich history in developing and commercializing new medicines to address infectious diseases including the recent FDA approval of HIV medication, Selzentry, said Dr. Mike Dunne, vice president, Infectious Disease Global Research and Development. As we move into the future, our scientists will focus even more on prevention and leverage the work of other therapeutic areas, not just to treat the infections themselves, but the consequences of those infections as well.

    Infectious disease represents a significant and constant threat. Today, infectious disease accounts for 21 percent of all disease-related morbidity and mortality, resulting in 12 million deaths annually. Infectious diseases are not only spreading faster, but they appear to be emerging more quickly than ever before. Since the 1970s, newly emerging diseases have been identified at the unprecedented rate of one or more per year. There are now nearly 40 diseases, such as HIV and HCV, that were unknown a generation ago.

    Investor Meeting Webcast:

    Pfizer Inc invites investors and the general public to listen to a webcast of a meeting with investment analysts to be held on Tuesday, September 18, at 6:00 p.m. Central Daylight Savings Time. The analyst meeting will include presentations by Pfizers anti-infective leadership team.

    To listen to the webcast, visit our web site at and click on the Pfizer Anti-infective at ICAAC link in the Investors Presentations tab on our homepage. Information on accessing and pre-registering for the webcast will be available at beginning today.

    Visitors will be able to view and listen to an archived copy of the webcast at

    Pfizer Inc
    Shreya Prudlo, 212-733-4889
    Sign up for the latest Pfizer Wire news alerts

    Receive real-time updates on Pfizer’s news delivered directly to your inbox.

    Our Pipeline: Potential Breakthroughs in the Making

    We're elevating our breakthroughs in a bold new way. Check out our new visualized product pipeline.

    Corporate Fact Sheet

    For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

    Media Asset Library

    Click here to view our media asset library.

    Pfizer Logo

    Our logo is shorthand for everything Pfizer represents: an image that is instantly identifiable to our colleagues, patients, the external scientific community, and the public.

    Executive Leadership

    Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company.

    Stay up to date on the latest news and alerts through the Pfizer Wire

    Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox. 


    Sign Up Now